Getting old through the blood. Circulating molecules in aging and senescence of cardiovascular regenerative cells by Angelini, Francesco et al.
Getting Old through the Blood: 
Circulating Molecules in Aging and
Senescence of Cardiovascular 
Regenerative Cells
 
October 2017 | Volume 4 | Article 621
Review
published: 06 October 2017
doi: 10.3389/fcvm.2017.00062
Frontiers in Cardiovascular Medicine | www.frontiersin.org
Edited by: 
Antonio Paolo Beltrami, 
University of Udine, Italy
Reviewed by: 
Marco Meloni, 
University of Edinburgh, 
United Kingdom  
Rajesh Katare, 





This article was submitted to 
Cardiovascular Biologics and 
Regenerative Medicine, 
a section of the journal 





Angelini F, Pagano F, Bordin A, 
Picchio V, De Falco E and Chimenti I 
(2017) Getting Old through the 
Blood: Circulating Molecules in Aging 
and Senescence of Cardiovascular 
Regenerative Cells. 
Front. Cardiovasc. Med. 4:62. 
doi: 10.3389/fcvm.2017.00062
Francesco Angelini, Francesca Pagano, Antonella Bordin, Vittorio Picchio, Elena De Falco 
and Isotta Chimenti*
Department of Medical Surgical Sciences and Biotechnologies, “La Sapienza” University of Rome, Latina, Italy
Global aging is a hallmark of our century. The natural multifactorial process resulting in 
aging involves structural and functional changes, affecting molecules, cells, and tissues. 
As the western population is getting older, we are witnessing an increase in the burden 
of cardiovascular events, some of which are known to be directly linked to cellular 
senescence and dysfunction. In this review, we will focus on the description of a few 
circulating molecules, which have been correlated to life span, aging, and cardiovascular 
homeostasis. We will review the current literature concerning the circulating levels and 
related signaling pathways of selected proteins (insulin-like growth factor 1, growth and 
differentiation factor-11, and PAI-1) and microRNAs of interest (miR-34a, miR-146a, miR-
21), whose bloodstream levels have been associated to aging in different organisms. In 
particular, we will also discuss their potential role in the biology and senescence of car-
diovascular regenerative cell types, such as endothelial progenitor cells, mesenchymal 
stromal cells, and cardiac progenitor cells.
Keywords: cell senescence, cardiac cell therapy, cardiovascular regeneration, insulin-like growth factor 1, 
endothelial progenitor cells, cardiac progenitor cells
iNTRODUCTiON
Aging is a natural multifactorial process of structural and functional changes, affecting molecules, 
cells, and tissues, therefore, representing a main risk factor for several clinical phenotypes, includ-
ing cardiovascular diseases and chronic conditions (1). It is undeniable that the incidence of car-
diovascular diseases, mainly heart failure, increases in the elderly population (2). Global aging is a 
hallmark of our century: the eldery population comprise roughly 15% of the population, and this 
scenario will increase of an additional 25% on average by 2050 (www.globalaginginstitute.org). This 
unprecedented population profile will inevitably imply, among others, an increasing burden of car-
diovascular events, some of which are directly linked to cellular senescence and dysfunction. Thus, 
increasing knowledge on the various mechanisms causing the progressive decline of cellular and 
tissue function may aid in developing therapies to delay or treat age-related conditions and diseases, 
such as diabetes, cardiovascular and neurodegenerative diseases (3). Consequently, the discovery 
of pathways responsible for increasing life span and health span, as both potential biomarkers and 
targets, is currently of primary interest.
Since impairment in endogenous tissue function and repair is particularly exacerbated in the 
elderly persons and is involved in physiological aging and in chronic diseases (4), novel approaches 
of regenerative personalized medicine are being currently explored in order to ameliorate future 
therapeutic options for the aged society. Accordingly, several regenerative cell populations have 
been considered and tested in preclinical and clinical settings in the last years for cardiovascular 
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applications, such as endothelial progenitor cells (EPCs) (5), 
mesenchymal stromal/stem cells (MSCs) (6), and resident cardiac 
progenitor cells (CPCs) (7, 8). Overall encouraging outcomes 
have been obtained in first clinical trials for several pathologies, 
such as revascularization strategies or cardiac cell therapy (5, 9), 
albeit with multiple issues still to be overcome (10).
Endothelial progenitor cells are considered a main circulating 
stem cell population finely controlling vascular homeostasis and 
repair in physiological conditions (11–14), therefore represent-
ing an interesting crossroad between circulating markers, 
regenerative cells, and aging mechanisms. According to their 
intrinsic property, EPCs represent per  se a valuable biomarker 
for monitoring pathological states, in particular those associated 
with vascular damage. Importantly, the demonstration that EPCs 
can be systemically recruited from the bone marrow-associated 
niche, and that after engraftment are able to replace old vasculature 
with new mature endothelial cells, has completely overturned the 
theory about aging (11, 12, 15) and can be considered a significant 
reference for the relationship between progenitor cells and aging. 
To date, EPCs represent one of the most studied example tools to 
rejuvenate the vascular system or to potentially delay the dam-
ages induced by aging. Specifically, aging implies, among others, 
profound derangements in the endothelium and consequently 
in EPCs in terms of either number or function, directly altering 
their ability to generate new vessels (16). Similarly, growth factors 
and hormones modulate endothelial function. According to this 
vision, endothelial responsiveness in both healthy subjects and 
patients with cardiac conditions has been improved by antiaging 
strategies based on administration of growth hormone (GH), 
which, among its many functions, has been reported to increase 
the number of circulating EPCs (17, 18). More importantly, in 
aged organisms where inflammation is exacerbated due to a 
dysregulated production of soluble mediators, a reduction in the 
biological properties of EPCs is consequently found. Mechanisms 
underlying these alterations are still to be fully elucidated, but are 
considered critical to unravel the modality by which a boosted 
turnover of the endothelial system can be achieved. However, 
they are hypothesized to be different when aging is the natural 
consequence of a physiological process compared to induced or 
premature aging, as after a pharmacological treatment.
The other cell populations of interest for cardiovascular 
regenerative protocols, particularly cell therapy for heart failure, 
are CPCs and MSCs. Resident CPCs have been isolated form 
heart tissue in adult mammals, including humans, with several 
protocols, albeit only two approaches (i.e., spheroid culture selec-
tion as “cardiospheres” and CD117-sorting) have reached enough 
preclinical evidence to support clinical translation (7, 8). CPCs 
have been shown to support cardiac regeneration by direct dif-
ferentiation toward cardiovascular lineages and paracrine effects 
(19, 20), and their biology and potency have been investigated 
in multiple settings (21, 22). MSCs have been introduced into 
clinical trials for cardiac cell therapy as well (23). They are mostly 
isolated from bone marrow and adipose tissue (24, 25), and con-
tribute to heart regeneration mainly by paracrine mechanisms 
mediating cardioprotection and modulation of inflammation 
(26). Many clinical trials with MSCs have been completed and 
are currently ongoing for regenerative purposes, making them 
another  important  candidate for advanced cardiovascular 
 therapies (23).
Notably, multiple studies suggest that, in the settings of cell 
transplantation for cardiovascular regenerative purposes, it is 
important not only to enhance intrinsic “young” properties of 
therapeutic cells, such as EPCs, but also to grant an ideal host 
microenvironment where engraftment can occur (27). Therefore, 
approaches able to rejuvenate regenerative cells and/or preserve 
tissue homeostasis and physiology (i.e., delaying overall aging) 
should be synergistically combined (16, 28).
One of the main mechanisms affecting senescence and aging 
at multiple levels is oxidative stress, which originates from several 
biochemical pathways triggered, among others, by environmental 
factors (29), and overall imbalancing the final amount of reac-
tive oxygen species (30). Their strict association with aging and 
cardiovascular cell senescence has been already extensively 
overviewed elsewhere (31). In this review, we will discuss few 
circulating molecules [proteins and microRNAs (miRNAs)], 
selected among those whose levels and related signaling pathways 
have been correlated to life span and healthy aging. In particular, 
we will discuss pathways with specific biological and rejuvenating 
roles in cellular senescence, cardiovascular functions, and with a 
potential or known role in the phenotype control of regenerative 
cell populations.
iNSULiN-LiKe GROwTH FACTOR 1 (iGF-1)
Growth hormone (GH) and IGF-1, a circulating polypeptide 
hormone rather similar in molecular structure to insulin (Ins), 
are two key molecules involved in one of the most evolution-
ary preserved age-regulator-pathway. In 1957 Salmon and 
Daughaday postulated the so called “somatomedin hypothesis” 
suggesting that the GH, produced by the pituitary gland, was 
able to stimulate IGF-1 release by the liver, promoting its 
somatogenic actions in the target tissues (32). Subsequently, the 
discovery of local production of IGF-1 in many tissues, such as 
the heart, led to update the original theory, conferring also to 
this peptide important autocrine and paracrine functions (33). 
The IGF system, consisting of Ins, IGF-1, and IGF-2, is able to 
regulate many cell functions by binding specific transmembrane 
receptors (InsR, IGF-1R, IGF-2R) or binding proteins (IGFBPs) 
(34). Among these latter, IGFBP-3 in particular, in association 
with another protein, the acid-labile subunits, binds circulating 
IGF-1, prolongs its half-life from less than 5 minutes to 16 hours 
(35), and regulates its activity (36, 37) (Figure  1). In fact, this 
150-kDa ternary complex serves as a potential reservoir of IGF-1 
by sequestering the growth factor in the vascular compartment, 
and once reached the tissues, IGF-1 is released from the complex 
by proteolysis of IGFBP-3 (38). It is well known that the secre-
tion of GH and IGF-1 declines progressively to very low levels 
with aging, a phenomenon called “somatopause” (39), and this 
evidence has suggested it as an hypothetical “longevity pathway” 
able to modulate aging processes (40).
Regarding the cardiovascular system, IGF-1 directly coop-
erates with the phosphatidylinositol 3-kinase (PI3K)/Akt/
mechanistic target of rapamycin (mTOR) signaling pathway, thus 
modulating the adaptive response of cardiac muscle to altered 
FiGURe 1 | A schematic panel of the circulating molecules analyzed in the text, aiming at underlining the connections between their different related pathways.
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conditions of hemodynamic overload, also known as physiologi-
cal hypertrophy (41). The PI3K/Akt/mTOR pathway is related to 
Ins sensitivity and calorie restriction (CR), which is the reduction 
of total caloric intake with an adequate balanced nutrition. CR 
is among the most well-known conditions able to increase life 
span and health span in different animal models (42). Since the 
PI3K/Akt/mTOR pathway is considered central in aging and Ins 
control (43), this strengthens the concept that endocrine factors, 
able to directly interact and coordinate PI3K/Akt/mTOR signal-
ing, could regulate longevity. It has been demonstrated that IGF-1 
induces an increase in cardiomyocyte size, with preserved systolic 
function and absence of fibrosis, and upregulates the expression 
of cardiac specific genes, such as troponin I and myosin light 
chain-2v (44, 45) (Figure 1). The same effect, in terms of attenu-
ation of left ventricular remodeling and enhancement of Akt 
signaling, is also indirectly promoted by an IGF-1-dependent 
myocardial SERCA2 content improvement (46). Regardless of 
these evidences, the mechanisms that link IGF-1, aging, and 
cardiovascular diseases are still debated. Several population 
studies have correlated an increased risk for all-cause mortality 
(including cardiovascular) to the presence of low circulating 
IGF-1 levels (47, 48). Analysis carried out on a specific exception-
ally long-living human population, though, have associated high 
IGF-1 levels found in centenarians with a compensatory effect 
due to genetic variants with reduced activity in IGF-1R signaling 
(49, 50), suggesting that high IGF-1 levels in elderly persons may 
be, at least in part, a compensatory mechanism. Nonetheless, 
Tran et al. (51) have suggested a molecular connection between 
IGF-1 and the sirtuin-1 (SIRT-1)/p53 pathway, responsible for 
inducing cell senescence (Figure  1). SIRT-1 is a well-known 
NAD-dependent deacetylase involved in aging. In fact, sirtuins 
are crucial during cell response to stress and for cell metabolism 
regulations, and their increasing levels, due to a proper lifestyle, 
are able to influence health span and, possibly, life span (52). 
Likewise, the role of p53 in promoting cellular senescence in 
response to cellular stress is also well demonstrated (53) by means 
of its inhibition through SIRT-1 deacetylation (54). It has been 
observed in vitro that IGF-1 treatment on human and murine pri-
mary fibroblasts is able to promote cell proliferation and survival 
in the short period, while a prolonged administration of IGF-1 
inhibits SIRT-1 deacetylase activity, increasing p53 acetylation 
and activation and leading to premature cell senescence (51).
Insulin-like growth factor 1 is known to have multiple effects 
on cardiovascular regenerative cells, such as resident CPCs. As 
previously mentioned, IGF-1 counteracts senescence and apop-
tosis in the heart (55), with the ability also to support the resident 
CPC pool (56) and enhance their homing in animal models of 
therapeutic protocols (57). Other than responding to IGF-1, 
CPCs release IGF-1 in an autocrine/paracrine way (19), thus 
potentially contributing to endogenous anti-senescent signals. 
When CPCs are cultured in 3D spheroid systems, mimicking the 
in vivo stem cell niche (58, 59), IGF-1 release is increased (19), 
and a highly controlled production of proteases (e.g., PAPP-A) 
against IGFBPs occurs, able to locally increase IGF-1 bioavailabil-
ity (60). Moreover, GH-induced IGF-1 increase has been shown 
in vivo to significantly attenuate cellular senescence of EPCs (61), 
which are considered per se as a circulating index of aging and 
impaired cardiovascular function (62). Overall, these results 
highlight an interesting relationship between IGF-1, as a circulat-
ing antagonist of aging, and its positive effects on the biology of 
cardiovascular regenerative cell types. We can speculate that this 
effect may be one of the beneficial mechanisms sustaining long 
lasting tissue homeostasis associated to high circulating IGF-1 
levels in long-living healthy mammals.
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GROwTH AND DiFFeReNTiATiON 
FACTOR-11 (GDF-11)
Another important and debated aging-related circulating factor, 
belonging to the transforming growth factor-β (TGF- β) super-
family, is the GDF-11 that is highly conserved in several species, 
including human, mice, rat, and invertebrates (63). The TGF-β 
superfamily has been divided into three main subclasses: TGF-βs, 
bone morphogenetics proteins, and activin/myostatins (MSTNs) 
(64). GDF-11 belongs to the activin/MSTNs subclass and regulates 
gene expression through phosphorylation of the signal trans-
ductors SMAD2 and SMAD3 (64). This complex migrates and 
accumulates in the nucleus to regulate gene expression through 
direct and indirect DNA binding (65, 66). Furthermore, several 
non-SMAD pathways have been discovered, such as PI3K/Akt/
mTOR signaling, by which GDF-11 regulates a variety of cellular 
functions (67) (Figure 1). Even if it is well known that GDF-11 
is involved in mesoderm formation and neurogenesis during 
embryonic development (68, 69), its role in postnatal tissues is 
less clear and still under investigation. It has been described as 
a mediator of aging processes in multiple tissues, particularly 
heart, brain, and muscle (70). GDF-11 role in aging in the car-
diovascular system was firstly investigated in 2013 by Loffredo 
et al. At first, they underlined an evident age-dependent decrease 
in circulating GDF-11 levels, and they cataloged this protein as a 
“pro-youthful” factor based on a parabiosis experiment (71). In 
fact, after exposing old mice to the circulation of young ones, they 
observed, through heart weight measurements, morphometric, 
and molecular analyses, a regression of cardiac hypertrophy 
levels comparable to those found in a young animal. However, 
in another study of daily injections of recombinant GDF-11 in 
old mice with the rationale to restore the level of this protein to 
youthful levels, the authors did not observe any improvement in 
the overall heart size, in cardiac myocytes volume, or any changes 
in cardiac performance (72). In the last years, many studies have 
investigated GDF-11 role on cardiac aging and remodeling, 
demonstrating the pros and cons of the “rejuvenating theory” in 
humans and other animal models (73–75), proving that, despite 
the controversy, this protein represents nonetheless a “hot spot” 
for understanding aging mechanisms and how to ameliorate life 
and health span.
Concerning the specific in vivo role of GDF-11 on cardiovas-
cular regenerative cells biology, it has been shown that targeted 
myocardial delivery of GDF-11 gene to the aged heart after ischae-
mia/reperfusion restored GDF-11 expression and contained 
tissue damage. GDF-11 levels were also associated to reduced 
cell senescence markers, increased proliferation of Sca-1+ CPCs, 
and increased homing of EPCs with angiogenesis in old ischemic 
hearts (76). Moreover, GDF-11 has been reported to be a key 
regulator of stem/progenitor cells phenotype and stemness 
control in multiple tissues, such as muscle and brain, where it is 
able to control proliferation, activation, and function of muscle 
satellite cells and neural stem cells, respectively (70). It is worth 
mentioning that skeletal myoblasts and satellite cells have been 
tested in the past as therapeutic cell products for cardiac cell 
therapy, although their clinical translation has been abruptly 
stopped due to dangerous arrhythmogenic side effects (22). 
A study by Finkenzeller et al., instead, has demonstrated in vitro 
that GDF-11 improves vasculogenesis by activating the Smad2/
Smad3 pathway using EPCs isolated from peripheral blood (pbE-
PCs) (77). Accordingly, future studies will be needed to provide 
further insights on the possible role of GDF-11 on the pheno-
type and senescence of cardiovascular regenerative cell types, 
including MSCs.
PAi-1
The circulating factors discussed until now have in common a 
negative correlation between their plasma concentration and 
increased age, and this defines them as possible, albeit partly 
debated, “rejuvenating” agents and/or aging biomarkers. However, 
it has been reported the existence of other important circulating 
factors which increase during aging, and could conversely repre-
sent an anti-aging target. Fibrinolysis, the proteolytic degradation 
of fibrin clots, is mediated by plasmin, which is formed through 
the activation of its precursor plasminogen by urokinase-type 
plasminogen activator and tissue-type plasminogen activator 
(t-PA) (78). The dynamic equilibrium of the fibrinolytic process is 
regulated also by the presence of specific inhibitors, such as alpha-
2-antiplasmin and plasminogen activator inhibitors (PAIs). These 
latters represent a family of serine-protease inhibitors, also known 
as serpins, composed by three types of PAI: PAI-1, PAI-2, and 
PAI-3 (79). In particular, plasma circulating factor PAI-1, despite 
its short half-life of around 2 hours (80), contributes substantially 
not only to fibrinolysis but also to a variety of biological processes, 
such as pericellular proteolysis, cell adhesion and migration, 
cell–matrix interactions, and signaling pathways (81–83).
High PAI-1 levels are involved in a number of age-related 
subclinical and clinical conditions, including Ins resistance and 
cardiovascular disease (84), as demonstrated analyzing several 
animal models of aging and/or population studies (85, 86). 
Recently, it has become evident that PAI-1 is synthesized and 
secreted by senescent cells and plays a critical role in the regula-
tion of aging. In fact, it has been demonstrated that PAI-1 is able 
to inhibit the proteolysis of IGFBP-3 by blocking t-PA, reducing 
accordingly IGF-1 release and inducing an accumulation of the 
inhibitor of cyclin-dependent kinases p16, leading to G1 cell cycle 
arrest and cellular senescence (87, 88) (Figure 1). Furthermore, 
Kortlever et al. have demonstrated that p53, in association with 
SMAD3, is able to upregulate PAI-1 expression in aging mice and 
human fibroblasts, causing a downregulation of PI3K signaling 
and cyclin nuclear exclusion (89, 90) (Figure 1). These findings 
were reinforced by Gosh et al. through a small molecule, called 
TM5441, which is a potent inhibitor of PAI-1. Indeed, they 
demonstrated that the pharmacological inhibition of PAI-1 has 
protective effect on aging-induced cellular senescence in cardiac 
myocytes, fibroblasts, and endothelial cells, suppressing specific 
regulators such as p16 and p53 (91).
Concerning cardiovascular regenerative cells, it has been 
recently demonstrated that kallistatin, a protein known to 
counteract vascular senescence, exerts its anti-senescent effects 
also through PAI-1 downregulation in EPCs, opposing TNF-α-
induced cellular signaling (92). Interestingly, increased PAI-1 
levels have been also shown to negatively affect the survival and 
FiGURe 2 | A schematic panel of the circulating microRNAs analyzed in the 
text and their related effects. ECM, extracellular matrix.
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anoikis resistance of therapeutic MSCs in ischemic-like condi-
tions (93), which is a main pathophysiological event in many 
cardiovascular diseases. Overall, these few studies suggest that 
targeting PAI-1 levels may be a strategic approach, among others, 
also to boost regenerative approaches.
CiRCULATiNG miRNAs
Among the circulating factors associated with aging, there are 
several miRNAs (94); these are small regulatory RNAs that can 
act as intracellular regulators or be secreted, and that mediate 
intercellular communication also through cellular junctions (95). 
These molecules can be released in the blood flow and are excep-
tionally stable in body fluids, including serum and plasma (96). 
Circulating miRNAs can be embedded into protein complexes 
(Ago2, Nucleophosmin-1), linked to lipoproteins such as high 
density lipoproteins, or within exosomes, microvescicles, and 
apoptotic bodies (97). These complexes protect the RNA from 
RNAse degradation and make circulating miRNAs eligible can-
didates as stable biomarkers and mediators for many pathological 
conditions, including cardiovascular diseases (98). A very recent 
review from Olivieri et al. discusses the most recent papers on the 
profiling of circulating miRNAs during aging in animal models, 
as well as human cohorts, providing a comprehensive review of 
the topic (99). Here, we will focus on few circulating miRNAs, 
which have been correlated to longevity (100, 101), and which 
have also a specific role in the biology of cardiac, vascular, and 
circulating progenitor cells.
Physiological aging can influence the amount of specific 
circulating miRNAs, as shown by studies in animal models and 
through comparison of elderly versus younger subjects (102), 
and some of them have a role in cardiovascular system biology 
and physiopathology (98). In line with several reports describing 
the effect of the microenvironment generated in the aging organ-
ism, a recent retrospective study on the circulating miRNome of 
twins has shown differences in circulating miRNAs levels as the 
twins age. Comparison of deceased twins with their alive co-twin 
brothers has showed that the profile and concentration of specific 
circulating miRNAs was different, and the different life span 
was reflected in a very dissimilar expression of the majority of 
miRNAs. This suggests that environmental factors are crucial for 
the presence of life expectancy-related circulating miRNAs (103).
The presence in the blood stream of miR-34 family members 
(miR-34 b/c) correlates with age in animal models (104), as well 
as in elderly subjects compared to younger (101, 105) (Figure 2). 
SIRT-1 is a well-studied miR-34-family target gene, and the 
miR-34-mediated downregulation of SIRT-1 has been shown 
to induce senescence in both endothelial cell lines and circulat-
ing EPCs in vitro (106, 107). In addition, miR-34 expression is 
increased in aorta smooth muscle cells during mice aging, and 
its high expression leads to the release of pro-inflammatory 
secretory factors from these cells (108), therefore contributing 
to detrimental vascular inflammatory states observed in aged 
organisms. Interestingly, miR-34a downregulation is mediated 
by the previously mentioned anti-senescent molecule, kallistatin, 
while consistently miR-34a overexpression is able to abolish 
kallistatin’s anti-senescent activity in EPCs (92). Finally, IGF-1 
can specifically block the expression of the precursor and mature 
miR-34a, while consistently miR-34a overexpression is able to 
abolish the antiapoptotic effect of IGF-1 (109). Overall this data 
support a role for this miRNA ranging from systemic circulating 
levels to local vascular and homeostatic effects.
A correlation between circulating miRNA levels and inflamma-
tory status has been also addressed in a study of genotype-by-age 
interaction in mice, which has revealed a peculiar miRNA pat-
tern in the blood of animals with different genotypes as they age. 
Specifically, miR-146a is increased in the aging control mice, but 
remains unchanged in the long-lived hypopituitary Ames dwarf 
mice (104), which in addition show reduced meta-inflammation 
(110). Concerning its effects on cardiovascular and regenerative 
cells, a direct effect of miR-146a on vascular cells’ survival has 
been described in animal models, where miR-146a overexpres-
sion induced vascular smooth muscle cells apoptosis through 
activation of the NF-KB signaling pathway (111) (Figure  2). 
Interestingly, features of increased functional cell yield and car-
diogenic potential in CPCs have been associated to reduced levels 
of miR-146a (112). Moreover, miR-146a overexpression has been 
shown to increase cell senescence in an EPC-enriched bone mar-
row cell population, impairing their angiogenic properties (113).
The levels of circulating miR-21 have been associated with 
longevity (105, 114): in fact, its downregulation is associated 
with healthy aging. This miRNA has many functions within the 
cardiovascular system; it has been described to induce cardiac 
fibroblasts senescence and extracellular matrix remodeling in the 
injured heart (115–117) (Figure  2). A recent in  vitro study on 
human circulating angiogenic progenitor cells (APCs) showed 
an effect of miR-21 increased expression in these adult cells, 
which are involved in vascular regeneration and homeostasis, 
as do EPCs. Overexpression of miR-21 is able to mediate APCs 
dysfunction through downregulation of superoxide dismutase 
2, and activation of Map–Erk kinase pathway through SPRY2 
inhibition. This resulted in impairment of nitric oxide availability 
and APC dysfunction (118), which ultimately might lead to lower 
reparative and regenerative capabilities. Consistently, increased 
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miR-21 expression levels have been also associated to features of 
reduced cardiovascular regenerative potential in human CPCs 
(112). Overall these studies suggest that, together with circulating 
proteins, epigenetic mediators may play a key role in physiologic 
aging mechanisms in the cardiovascular system, affecting local 
regenerative potential.
CONCLUSiON
In this review, we aimed at suggesting and discussing circulating 
molecules and related pathways in aging, whose understanding 
may potentially lead to the identification of diagnostic, prognos-
tic, or even therapeutic targets, albeit the available data do not 
allow definitive clinical stands yet. As discussed, multiple circu-
lating factors, ranging from proteins to RNAs to actual cells (i.e., 
EPCs), can be considered as aging mediators that offer interesting 
clues on senescence mechanisms and with potential diagnostic 
and therapeutic implications (Figures 1 and 2). Many of these 
factors have been associated with reduced regenerative potential 
and increased senescence of cell populations which are under 
preclinical and/or clinical investigation as cell product candidates 
for cardiovascular cell therapy protocols. Increasing knowledge 
on the relationship between circulating mediators and the path-
ways they may modulate (at both systemic and local level) may 
provide novel insights for the optimization and improvement of 
cardiovascular personalized regenerative medicine in the aging 
population.
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